Methylphenidate Composition Using Ascorbyl Esters Against Nitrosamines
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The formation of nitrosamines in pharmaceutical compositions containing methylphenidate, particularly due to the presence of secondary amines and nitrite impurities, poses a challenge for drug manufacturers, as nitrosamines are classified as probable human carcinogens.
Innovation Solution
Incorporating ascorbyl fatty acid esters, specifically at a molar ratio of 1:0.1 to 1:5 with methylphenidate, significantly reduces nitrosamine formation by reacting with potential nitrosating agents, thereby inhibiting the formation of nitrosamines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If methylphenidate is used to treat Attention Deficit Disorder, then therapeutic effectiveness is improved, but nitrosamine formation increases due to reaction with nitrite impurities
Solution Approach 1:
Ascorbyl fatty acid esters act as intermediary substances that preferentially react with nitrite impurities to form non-carcinogenic nitrosating products, thereby preventing the formation of carcinogenic N-nitrosomethylphenidate while allowing methylphenidate to maintain its therapeutic effect
Solution Approach 2:
The ascorbyl fatty acid esters convert the harmful nitrosation reaction into a beneficial process by directing nitrite reactivity toward forming harmless nitrosated ascorbyl derivatives instead of carcinogenic nitrosamines, thus transforming a safety hazard into a protective mechanism
2Object-affected harmful factors
If ascorbyl fatty acid esters are added to reduce nitrosamine formation, then safety is improved, but formulation complexity increases
Solution Approach 1:
Ascorbyl fatty acid esters serve multiple functions simultaneously: they act as antioxidants to prevent degradation, emulsifiers to improve formulation stability, and nitrosamine prevention agents by reacting with nitrite impurities, thereby reducing overall formulation complexity despite adding one ingredient
Solution Approach 2:
The invention specifies optimal molar ratios (1:0.1 to 1:5 of methylphenidate to ascorbyl fatty acid ester) and concentration ranges (0.01-10% w/w) to achieve effective nitrosamine prevention while minimizing formulation complexity and ensuring regulatory compliance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Ascorbyl fatty acid esters, particularly ascorbyl palmitate, effectively minimize nitrosamine formation in methylphenidate-containing compositions, ensuring safer pharmaceutical products.
Implementation Method 1
Nitrosamines are usually formed by a reaction of a secondary or tertiary amine with a nitrosating agent
Implementation Method 2
the formation of nitrosamines in compositions with methylphenidate can be significantly reduced by using an ascorbyl fatty acid ester
Data Source
AI summary
The present invention relates to the use of an ascorbyl fatty acid ester for reducing nitrosamine formation in compositions comprising methylphenidate.